Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842525 | 1.00 | TAAR1 (0.74) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL3285142 | 0.98 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL895673 | 0.93 | TAAR1 (0.79) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| Hydrochloric Acid SCHEMBL1027480 | 0.91 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002124 | 0.91 | TAAR1 (0.69) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL21002162 | 0.89 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL12630196 | 0.86 | SIGMAR1 (0.66) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL42400 | 0.85 | TAAR1 (1.00) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002016 | 0.85 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL29986862 | 0.85 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-0709376-B1 | Phenylpiperidino derivatives as neurokinin antagonists | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| EP-0709376-A2 | Therapeutic compounds | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| US-5028256-A | Metolachlor and an acylamide compound, for maize or sorghum | CIBA-GEIGY CORPORATION (US) | 1991-07-02 | — | — | US | disclosed |
| US-4897109-A | ACYLAMINE DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0163607-B1 | MEANS FOR THE PROTECTION OF CULTURE PLANTS AGAINST THE PHYTOTOXIC ACTION OF CHLORACETANILIDE HERBICIDES | CIBA-GEIGY AG (CH) | 1989-11-08 | — | — | EP | disclosed |
| EP-0163607-A2 | Means for the protection of culture plants against the phytotoxic action of chloracetanilide herbicides | CIBA-GEIGY AG (CH) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | TAAR1 634/4885CHRM2 38/4885CHRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.